Artios drug exploits ‘replication stress’ in cancer, shrinking subset of tumors in early study

Ryan Cross

Senior Science Correspondent

Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a subset of patients with advanced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Artios drug exploits ‘replication stress’ in cancer, shrinking subset of tumors in early study

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

Pfizer launches a new wave of cost cuts, expects $7.7B in total savings through 2027

FDA approves Abeona’s skin disease cell therapy

FDA won't reorganize medical product centers, Makary says in interview: 'I rejected that proposal'

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Ar­tios drug ex­ploits ‘repli­ca­tion stress’ in can­cer, shrink­ing sub­set of tu­mors in ear­ly study

Senior Science Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Artios drug exploits ‘replication stress’ in cancer, shrinking subset of tumors in early study